Clinical trials: Adalimumab
Psoriatic Arthritis
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
- Trial name
- Complete-PsA (NCT01559038)
- Where
- 41 sites in Canada
- Volunteers
- 483 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Behcet's Disease
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1.
- Trial name
- NCT01960790
- Volunteers
- 473 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
- Trial name
- NCT00646386
- Testing
- adalimumab
- Volunteers
- 315 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
The purpose of the study is to assess the safety and efficacy of adalimumab compared to placebo in subjects with rheumatoid arthritis on methotrexate therapy.
- Trial name
- NCT00235859
- Testing
- adalimumab, methotrexate
- Volunteers
- 128 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with…
- Trial name
- NCT02557100
- Testing
- Abatacept, Adalimumab, Methotrexate
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Juvenile Rheumatoid
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: Unknown adverse drug reactions (especially important adverse…
- Trial name
- NCT01412021
- Volunteers
- 375 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
Primary Objective: To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) in…
- Trial name
- NCT02332590
- Testing
- Sarilumab, Adalimumab
- Where
- 86 sites in United States, Chile and 13 more
- Volunteers
- 369 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis…
- Trial name
- RA-BRANCH (NCT04086745)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 119 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label…
- Trial name
- NCT00603993
- Testing
- Adalimumab
- Where
- 16 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Abbott
Pyoderma Gangrenosum
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
- Trial name
- NCT03311464
- Testing
- adalimumab
- Where
- 20 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AbbVie
Crohn's Disease
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
- Trial name
- CHARM (NCT00077779)
- Testing
- Adalimumab
- Where
- 43 sites in United States
- Volunteers
- 854 people
- Sponsor
- Abbott
Crohn's Disease
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
- Trial name
- CAPE (NCT02130362)
- Where
- 148 sites in United States, Bosnia and Herzegovina and 20 more
- Volunteers
- 1,446 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
In Israel, data is lacking regarding the long-term effectiveness of Adalimumab in outpatient real life setting. Moreover, the association between long-term effectiveness of Adalimumab and patients' functional status as well as…
- Trial name
- ORIENT (NCT02322723)
- Sponsor
- AbbVie
Polyarticular Juvenile Arthritis
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)
The objective of this study is to assess persistence, adherence and changes in disease activity in the children population of juvenile arthritis patients treated with adalimumab (HUMIRA®) in the routine clinical settings in the…
- Trial name
- PETITE (NCT03383263)
- Where
- 14 sites in Russia
- Volunteers
- 70 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics
To quantify the incremental cost of infections in patients treated with etanercept, adalimumab or infliximab versus abatacept.
- Trial name
- NCT01166620
- Volunteers
- 4,000 people
- Sponsor
- Bristol-Myers Squibb
Crohn's Disease
Special Investigation in Patients With Crohn's Disease (All Patients Investigation)
This study will be conducted to assess adverse drug reactions, incidence of adverse events, and factors that may affect the safety and effectiveness of Humira for the treatment of Crohn's disease.
- Trial name
- NCT01298648
- Where
- 1,131 sites in Japan
- Volunteers
- 1,716 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
The purpose of this study was to evaluate physical activity and its changes in participants with rheumatoid arthritis (RA) who were treated with adalimumab therapy in clinical practice.
- Trial name
- PACE (NCT01756235)
- Volunteers
- 462 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
Clinical Study of Stage IV Psoriasis in Children With Geleli
This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study.
- Trial name
- NCT05803187
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bio-Thera Solutions
Severe Crohn's Disease, Anxiety
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab
It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.
- Trial name
- RELAX (NCT01428115)
- Where
- 8 sites in Austria
- Volunteers
- 83 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn Disease, Ulcerative Colitis
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
A prospective, longitudinal, multicentre, observational cohort follow-up study conducted in France.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- SAPHIR (NCT05598684)
- Where
- 96 sites in France, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Fresenius Kabi, France